Abstract
In this issue of The Lancet Psychiatry, Jari Tiihonen and colleagues1 have investigated the slightly increased risk of rare haematological malignancies associated with long-term use of clozapine. This important finding needs to be contextualised to the risks and benefits associated with the use of clozapine for treatment-refractory schizophrenia.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
